Non-maturational covariates for dynamic systems pharmacology models in neonates, infants, and children: Filling the gaps beyond developmental pharmacology

被引:38
作者
Allegaert, Karel [1 ,2 ,3 ]
Simons, Sinno H. P. [4 ]
Tibboel, Dick [1 ,2 ]
Krekels, Elke H. [5 ]
Knibbe, Catherijne A. [5 ,6 ]
van den Anker, John N. [1 ,2 ,7 ,8 ]
机构
[1] Erasmus MC Sophia Childrens Hosp, Intens Care, Rotterdam, Netherlands
[2] Erasmus MC Sophia Childrens Hosp, Dept Pediat Surg, Rotterdam, Netherlands
[3] Katholieke Univ Leuven, Dept Dev & Regenerat, Leuven, Belgium
[4] Erasmus MC Sophia Childrens Hosp, Dept Pediat, Div Neonatol, Rotterdam, Netherlands
[5] Leiden Acad Ctr Drug Res, Div Pharmacol, Leiden, Netherlands
[6] St Antonius Hosp, Dept Clin Pharm, Nieuwegein, Netherlands
[7] Childrens Natl Hlth Syst, Div Clin Pharmacol, Washington, DC USA
[8] Univ Basel, Childrens Hosp, Div Pediat Pharmacol & Pharmacometr, Basel, Switzerland
关键词
Developmental pharmacology; Non-maturational covariates; Pediatrics; Neonatology; EXTRACORPOREAL MEMBRANE-OXYGENATION; AUGMENTED RENAL CLEARANCE; POPULATION PHARMACOKINETIC MODEL; RANDOMIZED-CONTROLLED-TRIAL; MORPHINE GLUCURONIDATION; GLOMERULAR-FILTRATION; VANCOMYCIN CLEARANCE; DRUG DISPOSITION; PRETERM NEWBORNS; P-GLYCOPROTEIN;
D O I
10.1016/j.ejps.2017.05.023
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacokinetics and - dynamics show important changes throughout childhood. Studies on the different maturational processes that influence developmental pharmacology have been used to create population PK/PD models that can yield individualized pediatric drug dosages. These models were subsequently translated to semi-physiologically or physiology-based PK (PBPK) models that support predictions in pediatric patient cohorts and other special populations. Although these translational efforts are crucial, these models should be further improved towards individual patient predictions by including knowledge on non-maturational covariates. These efforts are needed to ultimately get to systems pharmacology models for children. These models take developmental changes relating to the pediatric dynamical system into account but also other aspects that may be of importance such as abnormal body composition, pharmacogenetics, critical illness and inflammatory status.
引用
收藏
页码:S27 / S31
页数:5
相关论文
共 62 条
[1]   Population Pharmacokinetics of Midazolam and Its Metabolites during Venoarterial Extracorporeal Membrane Oxygenation in Neonates [J].
Ahsman, Maurice J. ;
Hanekamp, Manon ;
Wildschut, Enno D. ;
Tibboel, Dick ;
Mathot, Ron A. A. .
CLINICAL PHARMACOKINETICS, 2010, 49 (06) :407-419
[2]   Cerebrospinal fluid compartmental pharmacokinetics of amikacin in neonates [J].
Allegaert, K. ;
Scheers, I. ;
Adams, E. ;
Brajanoski, G. ;
Cossey, V. ;
Anderson, B. J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (06) :1934-1939
[3]   Pharmacological sedation management in the paediatric intensive care unit [J].
Baarslag, Manuel A. ;
Allegaert, Karel ;
Knibbe, Catherijne A. J. ;
van Dijk, Monique ;
Tibboel, Dick .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2017, 69 (05) :498-513
[4]   Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia [J].
Bastiaans, Diane E. T. ;
Swart, Eleonora L. ;
van Akkeren, Jesse P. ;
Derijks, Luc J. J. .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (02) :210-216
[5]   Altered gentamicin pharmacokinetics in term neonates undergoing controlled hypothermia [J].
Bijleveld, Yuma A. ;
de Haan, Timo R. ;
van der Lee, Hanneke J. H. ;
Groenendaal, Floris ;
Dijk, Peter H. ;
van Heijst, Arno ;
de Jonge, Rogier C. J. ;
Dijkman, Koen P. ;
van Straaten, Henrica L. M. ;
Rijken, Monique ;
Zonnenberg, Inge A. ;
Cools, Filip ;
Zecic, Alexandra ;
Nuytemans, Debbie H. G. M. ;
van Kaam, Anton H. ;
Mathot, Ron A. A. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (06) :1067-1077
[6]   Ontogeny of drug metabolizing enzymes in the neonate [J].
Blake, MJ ;
Castro, L ;
Leeder, JS ;
Kearns, GL .
SEMINARS IN FETAL & NEONATAL MEDICINE, 2005, 10 (02) :123-138
[7]   Semiphysiologically Based Pharmacokinetic Model for Midazolam and CYP3A Mediated Metabolite 1-OH-Midazolam in Morbidly Obese and Weight Loss Surgery Patients [J].
Brill, M. J. E. ;
Valitalo, P. A. J. ;
Darwich, A. S. ;
van Ramshorst, B. ;
van Dongen, H. P. A. ;
Rostami-Hodjegan, A. ;
Danhof, M. ;
Knibbe, C. A. J. .
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2016, 5 (01) :20-30
[8]   Impact of Obesity on Drug Metabolism and Elimination in Adults and Children [J].
Brill, Margreke J. E. ;
Diepstraten, Jeroen ;
van Rongen, Anne ;
van Kralingen, Simone ;
van den Anker, John N. ;
Knibbe, Catherijne A. J. .
CLINICAL PHARMACOKINETICS, 2012, 51 (05) :277-304
[9]   Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model [J].
Cook, Sarah F. ;
Stockmann, Chris ;
Samiee-Zafarghandy, Samira ;
King, Amber D. ;
Deutsch, Nina ;
Williams, Elaine F. ;
Wilkins, Diana G. ;
Sherwin, Catherine M. T. ;
van den Anker, John N. .
CLINICAL PHARMACOKINETICS, 2016, 55 (11) :1395-1411
[10]   Systems pharmacology - Towards the modeling of network interactions [J].
Danhof, Meindert .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 94 :4-14